Sjoerd H Van der Burg (Sjoerd H van der Burg, Sjoerd van der Burg)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 51

Top Topics

Systematic Review

Dendritic Cells

Top Venues

Journal for immunotherapy of cancer

Cancer immunology research

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Sjoerd H Van der Burg, Michael T Lotze
Perspectives from the leadership of Journal for ImmunoTherapy of Cancer . Journal for immunotherapy of cancer 12 (6) (2024)
Jessica S W Borgers, Tineke J van Wesemael, Kyra A Gelderman, Theo Rispens, Elizabeth M E Verdegaal, Dirk J A R Moes, Catharina M Korse, Ellen H W Kapiteijn, Marij J P Welters, Sjoerd H Van der Burg, Winan J van Houdt, Johannes V van Thienen, John B A G Haanen, Diane van der Woude
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Jessica S W Borgers, Tineke J van Wesemael, Kyra A Gelderman, Theo Rispens, Elizabeth M E Verdegaal, Dirk J A R Moes, Catharina M Korse, Ellen H W Kapiteijn, Marij J P Welters, Sjoerd H Van der Burg, Winan J van Houdt, Johannes V van Thienen, John B A G Haanen, Diane van der Woude
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Sjoerd H Van der Burg, Michael T Lotze
Perspectives from the leadership of Journal for ImmunoTherapy of Cancer . Journal for immunotherapy of cancer 12 (6) (2024)
Sjoerd H Van der Burg, Michael T Lotze
Perspectives from the leadership of Journal for ImmunoTherapy of Cancer . Journal for immunotherapy of cancer 12 (6) (2024)
Christianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen, Olivia Rensing, Camilla Labrie, Diana J M van den Wollenberg, Wytske M van Weerden, Matthew Coffey, Houra Loghmani, Elizabeth M E Verdegaal, Marij J P Welters, Sjoerd H Van der Burg, Thorbald van Hall, Nadine van Montfoort
Neutralizing antibodies impair the oncolytic efficacy of reovirus but permit effective combination with T cell-based immunotherapies. Cancer immunology research (2024)
Christianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen, Olivia Rensing, Camilla Labrie, Diana J M van den Wollenberg, Wytske M van Weerden, Matthew Coffey, Houra Loghmani, Elizabeth M E Verdegaal, Marij J P Welters, Sjoerd H Van der Burg, Thorbald van Hall, Nadine van Montfoort
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies. Cancer immunology research 12 (3) (2024)
Jessica S W Borgers, Tineke J van Wesemael, Kyra A Gelderman, Theo Rispens, Elizabeth M E Verdegaal, Dirk J A R Moes, Catharina M Korse, Ellen H W Kapiteijn, Marij J P Welters, Sjoerd H Van der Burg, Winan J van Houdt, Johannes V van Thienen, John B A G Haanen, Diane van der Woude
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Christianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen, Olivia Rensing, Camilla Labrie, Diana J M van den Wollenberg, Wytske M van Weerden, Matthew Coffey, Houra Loghmani, Elizabeth M E Verdegaal, Marij J P Welters, Sjoerd H Van der Burg, Thorbald van Hall, Nadine van Montfoort
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies. Cancer immunology research 12 (3) (2024)
Jessica S W Borgers, Tineke J van Wesemael, Kyra A Gelderman, Theo Rispens, Elizabeth M E Verdegaal, Dirk J A R Moes, Catharina M Korse, Ellen H W Kapiteijn, Marij J P Welters, Sjoerd H Van der Burg, Winan J van Houdt, Johannes V van Thienen, John B A G Haanen, Diane van der Woude
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Mandy van Gulijk, Anneloes van Krimpen, Sjoerd T T Schetters, Mike Eterman, Marit J van Elsas, Joanne M Mankor, Larissa Klaase, Marjolein J W de Bruijn, Menno van Nimwegen, Tim van Tienhoven, Wilfred F J Van IJcken, Louis Boon, Johan M S van der Schoot, Martijn Verdoes, Ferenc A Scheeren, Sjoerd H Van der Burg, Bart N Lambrecht, Ralph Stadhouders, Floris Dammeijer, Joachim Aerts, Thorbald van Hall
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Science immunology 8 (83) (2023)
Marit J van Elsas, Camilla Labrie, Anders Etzerodt, Pornpimol Charoentong, Jordi J C van Stigt Thans, Thorbald van Hall, Sjoerd H Van der Burg
Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. Journal for immunotherapy of cancer 11 (3) (2023)
Karien C M Gosens, Sjoerd H Van der Burg, Marij J P Welters, Sanne Boekestijn, Nikki M Loof, Wim G V Quint, Carel J M van Noesel, Allard C van der Wal, Olivier Richel, Wilhelmus J T A Krebber, Cornelis J M Melief, Henry John Christiaan de Vries, Jan M Prins
Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Marit J van Elsas, Camilla Labrie, Anders Etzerodt, Pornpimol Charoentong, Jordi J C van Stigt Thans, Thorbald van Hall, Sjoerd H Van der Burg
Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. Journal for immunotherapy of cancer 11 (3) (2023)
Jitske van den Bulk, Elizabeth M E Verdegaal, Manon van der Ploeg, Marten Visser, Joana B Nunes, Arnoud H de Ru, Rayman T N Tjokrodirijo, Marieke E Ijsselsteijn, Natasja I Janssen, Ruud van der Breggen, Linda de Bruin, Pita de Kok, George M C Janssen, Dina Ruano, Ellen H W Kapiteijn, Peter A van Veelen, Noel F C C de Miranda, Sjoerd H Van der Burg
Neoantigen targetability in progressive advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Mandy van Gulijk, Anneloes van Krimpen, Sjoerd T T Schetters, Mike Eterman, Marit J van Elsas, Joanne M Mankor, Larissa Klaase, Marjolein J W de Bruijn, Menno van Nimwegen, Tim van Tienhoven, Wilfred F J Van IJcken, Louis Boon, Johan M S van der Schoot, Martijn Verdoes, Ferenc A Scheeren, Sjoerd H Van der Burg, Bart N Lambrecht, Ralph Stadhouders, Floris Dammeijer, Joachim Aerts, Thorbald van Hall
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Science immunology 8 (83) (2023)
Christianne Groeneveldt, Jurriaan Q van Ginkel, Priscilla Kinderman, Marjolein Sluijter, Lisa Griffioen, Camilla Labrie, Diana J M van den Wollenberg, Wytske M van Weerden, Sjoerd H Van der Burg, Peter Ten Dijke, Lukas J A C Hawinkels, Thorbald van Hall, Nadine van Montfoort
Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy. Cancer research communications 3 (2) (2023)
Christianne Groeneveldt, Jurriaan Q van Ginkel, Priscilla Kinderman, Marjolein Sluijter, Lisa Griffioen, Camilla Labrie, Diana J M van den Wollenberg, Wytske M van Weerden, Sjoerd H Van der Burg, Peter Ten Dijke, Lukas J A C Hawinkels, Thorbald van Hall, Nadine van Montfoort
Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy. Cancer research communications 3 (2) (2023)
Mandy van Gulijk, Anneloes van Krimpen, Sjoerd T T Schetters, Mike Eterman, Marit J van Elsas, Joanne M Mankor, Larissa Klaase, Marjolein J W de Bruijn, Menno van Nimwegen, Tim van Tienhoven, Wilfred F J Van IJcken, Louis Boon, Johan M S van der Schoot, Martijn Verdoes, Ferenc A Scheeren, Sjoerd H Van der Burg, Bart N Lambrecht, Ralph Stadhouders, Floris Dammeijer, Joachim Aerts, Thorbald van Hall
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Science immunology 8 (83) (2023)
Elizabeth M E Verdegaal, Saskia J A M Santegoets, Marij J P Welters, Linda de Bruin, Marten Visser, Caroline E van der Minne, Pita M de Kok, Nikki M Loof, Sanne Boekestijn, Inge Roozen, Inge M Westra, Pauline Meij, Sjoerd H Van der Burg, Judith R Kroep
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer. Journal for immunotherapy of cancer 11 (11) (2023)
Ziena Abdulrahman, Natasja Hendriks, Arnold J Kruse, Antonios Somarakis, Anna J M van de Sande, Heleen J van Beekhuizen, Jurgen M J Piek, Noel F C C de Miranda, Loes F S Kooreman, Brigitte F M Slangen, Sjoerd H Van der Burg, Peggy J de Vos van Steenwijk, Edith M G van Esch
Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions. Journal for immunotherapy of cancer 10 (11) (2022)
Shidi Wu, Marion Rietveld, Marieke Hogervorst, Frank de Gruijl, Sjoerd H Van der Burg, Maarten H Vermeer, Remco van Doorn, Marij Welters, Abdoelwaheb El Ghalbzouri
Human Papillary and Reticular Fibroblasts Show Distinct Functions on Tumor Behavior in 3D-Organotypic Cultures Mimicking Melanoma and HNSCC. International journal of molecular sciences 23 (19) (2022)
Ziena Abdulrahman, Saskia J A M Santegoets, Gregor Sturm, Pornpimol Charoentong, Marieke E Ijsselsteijn, Antonios Somarakis, Thomas Höllt, Francesca Finotello, Zlatko Trajanoski, Sylvia L van Egmond, Dana A M Mustafa, Marij J P Welters, Noel F C C de Miranda, Sjoerd H Van der Burg
Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival. Journal for immunotherapy of cancer 10 (2) (2022)
Nadia de Gruil, Hanno Pijl, Sjoerd H Van der Burg, Judith R Kroep
Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity. Cancers 14 (6) (2022)
Chantal L Duurland, Saskia J A M Santegoets, Ziena Abdulrahman, Nikki M Loof, Gregor Sturm, Tom H Wesselink, Ramon Arens, Sanne Boekestijn, Ilina Ehsan, Mariette I E van Poelgeest, Francesca Finotello, Hubert Hackl, Zlatko Trajanoski, Peter Ten Dijke, Veronique M Braud, Marij J P Welters, Sjoerd H Van der Burg
CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors. Journal for immunotherapy of cancer 10 (1) (2022)
Kim E Kortekaas, Saskia J A M Santegoets, Liselotte Tas, Ilina Ehsan, Pornpimol Charoentong, Helena C van Doorn, Mariette I E van Poelgeest, Dana A M Mustafa, Sjoerd H Van der Burg
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy. Journal for immunotherapy of cancer 9 (10) (2022)
Marit J van Elsas, Johan M S van der Schoot, Alexander Bartels, Kas Steuten, Duco van Dalen, Zacharias Wijfjes, Carl G Figdor, Thorbald van Hall, Sjoerd H Van der Burg, Martijn Verdoes, Ferenc A Scheeren
Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody. International journal of molecular sciences 23 (15) (2022)
Marit van Elsas, Jan Willem Kleinovink, Matthijs Moerland, Gary Feiss, Guillaume Beyrend, Ramon Arens, Hailiang Mei, Peter H Nibbering, Silvana M Jirka, Thorbald van Hall, Sjoerd H Van der Burg
Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models. Journal for immunotherapy of cancer 8 (2) (2021)
Cornelis J M Melief, Marij J P Welters, Ignace Vergote, Judith R Kroep, Gemma G Kenter, Petronella B Ottevanger, Wiebren A A Tjalma, Hannelore Denys, Mariette I E van Poelgeest, Hans W Nijman, Anna K L Reyners, Thierry Velu, Frederic Goffin, Roy I Lalisang, Nikki M Loof, Sanne Boekestijn, Willem Jan Krebber, Leon Hooftman, Sonja Visscher, Brent A Blumenstein, Richard B Stead, Winald R Gerritsen, Sjoerd H Van der Burg
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Science translational medicine 12 (535) (2021)
Ziena Abdulrahman, Noel F C C de Miranda, Edith M G van Esch, Peggy J de Vos van Steenwijk, Hans W Nijman, Marij J P Welters, Mariette I E van Poelgeest, Sjoerd H Van der Burg
Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination. Journal for immunotherapy of cancer 8 (1) (2021)
Sjoerd H Van der Burg
IL11: A Specific Repressor of Tumor-Specific CD4+ T Cells. Cancer immunology research 9 (7) (2021)
Joosje C Baltussen, Marij J P Welters, Elizabeth M E Verdegaal, Ellen H W Kapiteijn, Anne M R Schrader, Marije Slingerland, Gerrit-Jan Liefers, Sjoerd H Van der Burg, Johanneke E A Portielje, Nienke A de Glas
Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. Cancers 13 (24) (2021)
Saskia J A M Santegoets, Chantal L Duurland, Ekaterina J Jordanova, Vanessa J van Ham, Ilina Ehsan, Nikki M Loof, Vipin Narang, Charles A Dutertre, Florent Ginhoux, Sylvia L van Egmond, Marij J P Welters, Sjoerd H Van der Burg
CD163+ cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer. Journal for immunotherapy of cancer 8 (2) (2021)
Elizabeth M E Verdegaal, Monique K Van der Kooij, Marten Visser, Caroline van der Minne, Linda de Bruin, Pauline Meij, Anton Terwisscha van Scheltinga, Marij J Welters, Saskia Santegoets, Noel F C C de Miranda, Inge Roozen, Gerrit Jan Liefers, Ellen Kapiteijn, Sjoerd H Van der Burg
Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study. Journal for immunotherapy of cancer 8 (1) (2021)
Anouk Corbeau, Remi A Nout, Jan Willem M Mens, Nanda Horeweg, Jérémy Godart, Ellen M Kerkhof, Sander C Kuipers, Mariette I E van Poelgeest, Judith R Kroep, Ingrid A Boere, H Lena C van Doorn, Mischa S Hoogeman, Uulke A van der Heide, Hein Putter, Marij J P Welters, Sjoerd H Van der Burg, Carien L Creutzberg, Stephanie M de Boer
PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System. Cancers 13 (20) (2021)
Christianne Groeneveldt, Priscilla Kinderman, Diana J M van den Wollenberg, Ruben L van den Oever, Jim Middelburg, Dana A M Mustafa, Wytske M van Weerden, Sjoerd H Van der Burg, Thorbald van Hall, Nadine van Montfoort
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy. Journal for immunotherapy of cancer 8 (2) (2021)
Marit M Melssen, Robin S Lindsay, Katarzyna Stasiak, Anthony B Rodriguez, Amanda M Briegel, Salwador Cyranowski, Melanie R Rutkowski, Mark R Conaway, Cornelis J M Melief, Sjoerd H Van der Burg, Ukpong Eyo, Craig L Slingluff, Victor H Engelhard
Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. Cancer immunology research 9 (5) (2021)
Elham Beyranvand Nejad, Camilla Labrie, Ziena Abdulrahman, Marit J van Elsas, Eva Rademaker, Jan Willem Kleinovink, Tetje C van der Sluis, Suzanne van Duikeren, Amina F A S Teunisse, Aart G Jochemsen, Jan Oosting, Noel F C C de Miranda, Thorbald van Hall, Ramon Arens, Sjoerd H Van der Burg
Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy. Journal for immunotherapy of cancer 8 (2) (2021)
Daniel P Hurkmans, Elizabeth M E Verdegaal, Sabrina A Hogan, Rik de Wijn, Lies Hovestad, Dianne M A van den Heuvel, Rob Ruijtenbeek, Marij J P Welters, Mandy van Brakel, Edwin A Basak, Herbert M Pinedo, Cor H J Lamers, Harmen J G van de Werken, John P Groten, Reno Debets, Mitchell Paul Levesque, Reinhard Dummer, Ellen Kapiteijn, Ron H J Mathijssen, Joachim G J V Aerts, Sjoerd H Van der Burg
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. Journal for immunotherapy of cancer 8 (2) (2021)
Elham Beyranvand Nejad, Camilla Labrie, Marit J van Elsas, Jan Willem Kleinovink, Hans-Willi Mittrücker, Kees L M C Franken, Sylvia Heink, Thomas Korn, Ramon Arens, Thorbald van Hall, Sjoerd H Van der Burg
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. Journal for immunotherapy of cancer 9 (4) (2021)
Linda Borst, Sjoerd H Van der Burg, Thorbald van Hall
The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (21) (2020)
Kim E Kortekaas, Saskia J Santegoets, Gregor Sturm, Ilina Ehsan, Sylvia L van Egmond, Francesca Finotello, Zlatko Trajanoski, Marij J P Welters, Mariette I E van Poelgeest, Sjoerd H Van der Burg
CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer. Cancer immunology research 8 (10) (2020)
Elham Beyranvand Nejad, Camilla Labrie, Tetje C van der Sluis, Suzanne van Duikeren, Kees L M C Franken, Rueshandra Roosenhoff, Ramon Arens, Thorbald van Hall, Sjoerd H Van der Burg
Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function. International journal of cancer 148 (1) (2020)
Shu-Chen Hung, Tieying Hou, Wei Jiang, Nan Wang, Shuo-Wang Qiao, I-Ting Chow, Xiaodan Liu, Sjoerd H Van der Burg, David M Koelle, William Wai-Hung Kwok, Ludvig M Sollid, Elizabeth D Mellins
Epitope Selection for HLA-DQ2 Presentation: Implications for Celiac Disease and Viral Defense. Journal of immunology (Baltimore, Md. : 1950) 202 (9) (2019)
Monique K Van der Kooij, Frank M Speetjens, Sjoerd H Van der Burg, Ellen Kapiteijn
Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. Cancers 11 (6) (2019)
Tom J Harryvan, Elizabeth M E Verdegaal, James C H Hardwick, Lukas J A C Hawinkels, Sjoerd H Van der Burg
Targeting of the Cancer-Associated Fibroblast-T-Cell Axis in Solid Malignancies. Journal of clinical medicine 8 (11) (2019)
Kim E Kortekaas, Saskia J Santegoets, Ziena Abdulrahman, Vanessa J van Ham, Marij van der Tol, Ilina Ehsan, Helena C van Doorn, Tjalling Bosse, Mariëtte I E van Poelgeest, Sjoerd H Van der Burg
High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status. Journal for immunotherapy of cancer 7 (1) (2019)
Wenbo Ma, Fernando Concha-Benavente, Saskia J A M Santegoets, Marij J P Welters, Ilina Ehsan, Robert L Ferris, Sjoerd H Van der Burg
EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer. PloS one 13 (9) (2018)
Mark J de Lange, Rogier J Nell, Rajshri N Lalai, Mieke Versluis, Ekaterina S Jordanova, Gre P M Luyten, Martine J Jager, Sjoerd H Van der Burg, Willem H Zoutman, Thorbald van Hall, Pieter A van der Velden
Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma. Molecular cancer research : MCR 16 (12) (2018)
Koen A Marijt, Laura Blijleven, Elizabeth M E Verdegaal, Michel G Kester, Daniel J Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic, Mirjam H M Heemskerk, Sjoerd H Van der Burg, Thorbald van Hall
Identification of non-mutated neoantigens presented by TAP-deficient tumors. The Journal of experimental medicine 215 (9) (2018)
Saskia J Santegoets, Vanessa J van Ham, Ilina Ehsan, Pornpimol Charoentong, Chantal L Duurland, Vincent van Unen, Thomas Höllt, Lilly-Ann van der Velden, Sylvia L van Egmond, Kim E Kortekaas, Peggy J de Vos van Steenwijk, Mariëtte I E van Poelgeest, Marij J P Welters, Sjoerd H Van der Burg
The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (1) (2018)